within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP53_OmbitasvirParitaprevirAn;

model OmbitasvirParitaprevirAn
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.7,
    Cl = 1.5555555555555556e-06,
    adminDuration = 600,
    adminMass = 25 / 1000000,
    adminCount = 1,
    Vd = 0.104,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.009166666666666667,
    Tlag = 10.200000000000001,
    Vdp = 0.259,
    k12 = 1.222222222222222e-05,
    k21 = 1.222222222222222e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>OmbitasvirParitaprevirAndRitonavir</td></tr><tr><td>ATC code:</td><td>J05AP53</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>25</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>104</td><td>L</td></tr>
    <tr><td>clearance:</td><td>5.6</td><td>L/h/ombitasvir</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ombitasvir, paritaprevir, and ritonavir is a fixed-dose combination antiviral medication used in the treatment of chronic hepatitis C virus (HCV) infection. Ombitasvir is an NS5A inhibitor, paritaprevir is an NS3/4A protease inhibitor, and ritonavir acts as a pharmacokinetic enhancer by inhibiting CYP3A-mediated metabolism of paritaprevir. This combination is approved for use in many countries and was commonly marketed as part of the Viekira Pak regimen.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration of the co-formulated combination under fed conditions.</p><h4>References</h4><ol><li><p>Mensing, S, et al., &amp; Dutta, S (2016). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. <i>The AAPS journal</i> 18(1) 270–280. DOI:<a href=\"https://doi.org/10.1208/s12248-015-9846-1\">10.1208/s12248-015-9846-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26597291/\">https://pubmed.ncbi.nlm.nih.gov/26597291</a></p></li><li><p>Gopalakrishnan, SM, et al., &amp; Menon, RM (2017). Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection. <i>Clinical pharmacokinetics</i> 56(1) 1–10. DOI:<a href=\"https://doi.org/10.1007/s40262-016-0423-2\">10.1007/s40262-016-0423-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27314261/\">https://pubmed.ncbi.nlm.nih.gov/27314261</a></p></li><li><p>Minaei, AA, &amp; Kowdley, KV (2015). ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. <i>Expert opinion on pharmacotherapy</i> 16(6) 929–937. DOI:<a href=\"https://doi.org/10.1517/14656566.2015.1024653\">10.1517/14656566.2015.1024653</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25800085/\">https://pubmed.ncbi.nlm.nih.gov/25800085</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AP53 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end OmbitasvirParitaprevirAn;
